Arcutis Biotherapeutics, INC Form 4 insider transactions

Director Patrick J. Heron reports purchases of Arcutis Biotherapeutics stock through various entities and trusts.

Director Patrick J. Heron reports purchasing 6,300 shares of Arcutis Biotherapeutics at an average price of $13.6018 on May 9, 2025.

Executive Vice President and Chief Medical Officer of Arcutis Biotherapeutics, Patrick Burnett, sold 3,871 shares of common stock at an average price of $13.5942 under a pre-arranged 10b5-1 trading plan.

Latha Vairavan, CFO of Arcutis Biotherapeutics, reports the acquisition of restricted stock units and stock options.

Masaru Matsuda, SVP General Counsel and Corporate Secretary of Arcutis Biotherapeutics, sold 5,030 shares of common stock to cover tax withholding obligations related to vesting Restricted Stock Units.

Arcutis Biotherapeutics CEO Todd Franklin Watanabe sold 11,448 shares of common stock on May 2, 2025, at a weighted average price of $15.1919 to cover tax withholding obligations related to vesting Restricted Stock Units.

Executive Vice President and Chief Medical Officer of Arcutis Biotherapeutics, Patrick Burnett, sold 2,597 shares of common stock to cover tax withholding obligations related to vesting Restricted Stock Units.

Director Howard G. Welgus sold 10,000 shares of Arcutis Biotherapeutics (ARQT) common stock on May 1, 2025, at a weighted average price of $14.6357, under a pre-arranged 10b5-1 trading plan.

Director Howard G. Welgus sold 10,000 shares of Arcutis Biotherapeutics (ARQT) common stock at an average price of $15.1236, executed under a pre-arranged 10b5-1 trading plan.

David Joseph Topper, CFO of Arcutis Biotherapeutics, sold 9,600 shares of common stock on April 2, 2025, to cover tax withholding obligations related to the vesting of Restricted Stock Units.

Arcutis Biotherapeutics CEO Todd Franklin Watanabe sold shares of the company's common stock on March 24 and 25, 2025, under a pre-arranged 10b5-1 trading plan.

Arcutis Biotherapeutics CEO Todd Franklin Watanabe sold 1,200 shares of common stock at an average price of $17.6142, pursuant to a pre-arranged 10b5-1 trading plan.

Executive Vice President and Chief Medical Officer of Arcutis Biotherapeutics, Patrick Burnett, reports the sale of common stock under a pre-arranged 10b5-1 trading plan.

Executive Vice President and Chief Medical Officer of Arcutis Biotherapeutics, Patrick Burnett, reports acquisition and disposal of common stock and stock options related to vesting of restricted stock units.

Arcutis Biotherapeutics CEO Todd Watanabe reports acquisition of restricted stock units and sales of common stock to cover tax obligations.

David Topper, CFO of Arcutis Biotherapeutics, reports the acquisition of 34,000 shares of common stock and options to purchase 89,000 shares.

Director Howard G. Welgus sold 10,000 shares of Arcutis Biotherapeutics (ARQT) at an average price of $13.0048 on March 3, 2025, under a pre-arranged 10b5-1 trading plan.

Larry Todd Edwards, Executive Vice President and Chief Commercial Officer of Arcutis Biotherapeutics, reports acquisition of shares and stock options.

Masaru Matsuda, General Counsel and Corporate Secretary of Arcutis Biotherapeutics, reports acquisition of restricted stock units and stock options, as well as the sale of shares to cover tax obligations.

Masaru Matsuda, Senior Vice President, General Counsel, and Corporate Secretary of Arcutis Biotherapeutics, sold shares to cover tax obligations related to vesting Restricted Stock Units.

Arcutis Biotherapeutics CEO Todd Watanabe sold 19,301 shares of common stock on February 3, 2025, to cover tax withholding obligations related to the vesting of Restricted Stock Units.

Director Howard G. Welgus sold 10,000 shares of Arcutis Biotherapeutics (ARQT) at an average price of $12.71 on February 3, 2025, under a pre-arranged 10b5-1 trading plan.

Patrick Burnett, Executive Vice President and Chief Medical Officer of Arcutis Biotherapeutics, sold shares to cover tax withholding obligations related to vesting Restricted Stock Units.

Larry Todd Edwards, an executive at Arcutis Biotherapeutics, sold shares to cover tax withholding obligations related to vesting restricted stock units.

Director Howard G. Welgus sold 10,000 shares of Arcutis Biotherapeutics (ARQT) common stock at an average price of $14.6714, pursuant to a pre-arranged 10b5-1 trading plan.

An Arcutis Biotherapeutics executive sold 1,691 shares of common stock to cover tax obligations related to vesting performance-based Restricted Stock Units.

Arcutis Biotherapeutics CEO, Todd Franklin Watanabe, sold 15,000 shares of common stock at an average price of $15.1711, as part of a pre-arranged 10b5-1 trading plan.

Larry Todd Edwards, an executive at Arcutis Biotherapeutics, acquired 1,093 shares of common stock through the company's Employee Stock Purchase Plan.

Masaru Matsuda, a Senior Vice President at Arcutis Biotherapeutics, acquired additional shares of company stock through the Employee Stock Purchase Plan.

Arcutis Biotherapeutics director Howard G. Welgus sold 10,000 shares of common stock at a weighted average price of $12.5133 per share, as part of a pre-arranged 10b5-1 trading plan.